Public recall detail

JAMP Digoxin tablets: One lot recalled due to possible oversized tablets which may pose overdose risk

2024-05-31

medium
Recall Safety notice
Quick summary

Quick summary: JAMP Digoxin tablets: One lot recalled due to possible oversized tablets which may pose overdose risk. Date: 2024-05-31.

Recommended action

Recommended action: compare your product with the official notice and follow the instructions published by the official source.

Recall details

Quick summary: JAMP Digoxin tablets: One lot recalled due to possible oversized tablets which may pose overdose risk. Date: 2024-05-31.

Official details

Affected product details

Structured information extracted from the official recall notice. Confirm the identifiers and instructions in the original notice.

Brand
ProductJAMP Digoxin 0.0625 mg tablets (lot EG23DGX001, expiry 07-2025)
IssueHealth products - Product safety
IdentificationRA-75604

Affected products

ProductJAMP Digoxin 0.0625 mg tablets
DIN / NPN / authorization02498502
LotEG23DGX001
Codes07-2025

Issue

JAMP Pharma Corporation is recalling one lot of JAMP Digoxin 0.0625 mg tablets as some bottles may contain thicker, oversized tablets. Patients taking an oversized tablet will unexpectedly receive a higher dose than intended, which may pose serious health risks, including overdose. Digoxin is a drug where small differences in dose or blood concentration can lead to side effects, therefore it is very important that all patients taking the affected JAMP product return it to the pharmacy for replacement. JAMP Digoxin is a prescription drug used in children and adults to treat mild to moderate congestive heart failure. It can also be used to treat a fast or irregular heartbeat (e.g., atrial fibrillation). Signs and symptoms of a digoxin overdose may include nausea, vomiting, decreased appetite, diarrhea, confusion, seizures, hallucinations, vision effects (seeing light "halos" around objects, or green or yellow vision), fatigue, irregular heartbeat, and abnormally fast or slow heartbeat. In cases of severe overdose, heart-related effects could be life threatening. Children, people over the age of 65, and people who have an electrolyte or thyroid disorder may be at a higher risk of adverse effects. Health Canada is monitoring the company's recall and its implementation of any necessary corrective and preventative actions to stop this issue from reoccurring. The Department will inform the public if any new health risks are identified.

What you should do

  • Return your JAMP Digoxin 0.0625 mg tablets to your pharmacy for replacement as soon as possible. Until you can return them, continue to take your JAMP Digoxin but do not take tablets that look oversized (see image, which shows an oversized tablet on the left and proper-sized tablet on the right). If you are unsure whether your product is affected, check with your pharmacy.
  • Contact a health care professional immediately if you or someone you are caring for experience serious side effects.
  • Contact JAMP Pharma Corporation by calling toll-free at 1-866-399-9091, extension 501, or by email at custjamp@jamppharma.com, if you have questions about this recall.
  • Report any health product-related side effects or complaints to Health Canada.
  • Health care professionals, such as pharmacists, should check bottles of JAMP Digoxin 0.0625 mg tablets before dispensing and report any unusual tablets to the company and to Health Canada.
Additional official information
AudienceIdentification number RA-75604
CategoryHealth products
CompaniesPublished by Health Canada
Published byHealth Canada
Alert / recall typePublic advisory
Identification numberRA-75604
Background{}
CompaniesPublished by Health Canada
AudiencesIdentification number RA-75604
Source updated2024-05-31

Contains information licensed under the Open Government Licence – Canada. SafetyPulse is independent of the Government of Canada.

Starting...

Related recalls

Similar recalls and safety notices.

Loading related recalls...